Lilly reports losses on ImClone charge
This article was originally published in Scrip
Executive Summary
Lillyswung to a hefty loss during the fourth quarter following its purchase of ImClone Systemsfor $6.3 billion in November. The charges also weighed down full-year earnings, as did a settlement with the US justice department on Zyprexa (olanzapine).